Rius Medical

Rius Medical – Innovative Science and Technology are at the Heart of Everything we do!

For the few investors seeking life sciences venture in early-stage companies, this announcement bring fourth innovative new ideas where Artificial Intelligence combine with innovative biotech technologies speed up development process of therapeutics to address the current and future Coronavirus outbreaks.

[Reuters, July 2020] Six months into a global COVID-19 pandemic that has infected more than 12 million people, questions remain about whether the antibody response to this virus is robust and lasts over time www. As scientists question whether the presence, or absence, of antibodies to the novel Coronavirus can reliably determine immunity, some are looking to a different component of the immune system, known as T cells, for their role in protecting people in the pandemic.

[Blog, July 2020] Dr. Francis Collins, Director of the United States National Institutes of Health (NIH) commented the following: Much of the study on the immune response to SARS-CoV-2, the novel Coronavirus that causes COVID-19, has focused on the production of antibodies. But, in fact, immune cells known as memory T cells also play an important role in the ability of our immune systems to protect us against many viral infections, including – it now appears – COVID-19 www. What’s clear from this study “by Bertoletti’s team” is our past experiences with Coronavirus infections may have something important to tell us about COVID-19.

Artificial Intelligence comes to the rescue in taming the Coronavirus literature www. AI and biomedical Developers are a great union. The COVID-19 literature has grown in much the same way as the disease’s transmission: exponentially. Artificial Intelligence refers to a broader idea where machines can execute tasks "smartly".  Artificial Intelligence (AI) applies machine learning, deep learning and other techniques to solve actual problems. Deep learning is an artificial intelligence function that imitates the workings of the human brain in processing data and creating patterns for use in decision-making. The goal is to provide an even more powerful environment for mining COVID-19 literature that lists more than 28,000 articles — far too many for any researcher/scientist to read.

Investors seeking technologies to improve lives and generate returns, here with Rius Medical, are welcome to inquirer on Rius Medical’s cutting-edge technology that also enlist Artificial Intelligence to improve lives and generate returns! Your investment in Rius Medical “Scale up” manufacturing processes for multiple products also enables the development of therapeutics to address the current and future Coronavirus outbreaks.

Are you against a brief 3 minutes talk to learn more?

Many thanks and warmest regards,

Denis Demarais
Founder and CEO
Email: denisdemarais@riusmedical.de

Rius Medical has made it its mission to further support the cell and gene therapy industry by channelling its expertise into developing technologies that enables “scale up” manufacturing processes.

Rius Medical develops proprietary cell lines for drug delivery. What we do are novel protein therapeutics and a drug delivery technology combine. The Rius Medical project is available to all investors, as published on EuroQuity ¹ and on European Investment Project Portal (EIPP) ². On Angel Invest Network (UK) www Rius Medical is seeking from business angels up to EUR 50,000 Convertible Loan at a discounted rate of 0.50 euro per share.

Lead Investor, Resource Link Consulting Group transferred EUR 1,000,000 financing and pending EUR 24,000 surety bond payment, this project is implemented as of September 2020. An additional EUR 400,000 investment is pending the second investor Sanabil Investments, a sovereign wealth fund of Saudi Arabia completing Due Diligence. Otherwise 8% ownership at EUR 400,000 is available to other investors.

Addressing Coronavirus is with NK cells manufacturing and providing Blood for transfusion! January 2020, Sorrento and Celularity initiated Emergency Allogeneic Natural Killer Cell Therapy Development for Coronavirus Infection www. It is the view of Rius Medical that addressing the 2019 Coronavirus outbreak must exploit NK cells as a therapeutic agent. Rius Medical believes that off-the-shelf natural killer (NK) cells therapy is to be the primary weapon in addressing the 2019 Coronavirus outbreak. The attached documents highlights why that is the case.

Regardless of the form, are we on the right track with Coronavirus vaccine? March 17, 2020, the European Commission offered up to EUR 80 million in financial support to the German biotech CureVac AG (RNA-based vaccine) after it was reported that US President Donald Trump attempted to secure exclusive access to a COVID-19 vaccine CureVac is developing www. As a secondary weapon, it is Rius Medical view that vaccine development must be performed. However, the documents in attachment highlight my support for an alternative as primary weapon. That’s because vaccines utilising mRNA platforms remain an unproven technology, with no vaccine approved for use to date www.

Bottom Line for EUR 25,000 investment: An investment of EUR 25,000 as Convertible Loan at a discounted rate of 0.50 euro per share implies EUR 2,700,000 financial benefits on FIVE products, if not EUR 525,000 financial benefits on TWO products at year 2 (i.e. December 2021). Alternatively there is the option of EUR 25,000 Classical LOAN (1 year maturity, yet full repayment at the latest mid-September 2020) with 30% interest p.a. for EUR 32,500 repayment. More information is available in the attachments.

Are you against a brief 3 minutes talk to learn more?

Many thanks and warmest regards,

Denis Demarais

Founder and CEO

Email: denisdemarais@riusmedical.de

Dear investors/Business angels,

It is the view of Rius Medical that addressing the 2019 Coronavirus outbreak must exploit NK cells as a therapeutic agent. Rius Medical believes that off-the-shelf natural killer (NK) cells therapy is to be the primary weapon in addressing the 2019 Coronavirus outbreak.

In the recently uploaded document: “Coronavirus vaccine as secondary weapon!” you will find why Rius Medical implements NK cells as the primary weapon!

Best regards,

Denis Demarais
Founder and CEO
Email: denisdemarais@riusmedical.de         

Dear Investors / Business Angels,

With Proprietary cell lines for drug delivery, Rius Medical brings novel protein therapeutics and a drug delivery technology for multiple products, as published on European Investment Project Portal (EIPP) www. As a service provider/contractor, you will find Rius Medical primarily in partnership and cooperation with business partners to bring products to the market in 2 years (i.e. within Year 2021).

Planned use of the EUR 20,000 investment: liquidity for the payment of EUR 25,600 surety bond in relation to the release of EUR 1,000,000 equity capital in the escrow account of Rius Medicals at Accrued Equities Inc.

Stem cell applications will revolutionize medicine and therapies! At the Annual Meeting of the World Economic Forum 2020 in Davos (21-24 January 2020 www), the current market for stem cell therapies grew by 36% per year and will rapidly expand as a groundbreaking treatment for non-communicable diseases or as a lifestyle factor. With greater resources and an increasingly experienced talent pool, scientists and doctors may be able to develop stem cell research to cure the world's most difficult diseases.

NK cells manufacturing against Coronavirus is in development since January 2020 with Sorrento and Celularity initiating Emergency Allogeneic Natural Killer Cell Therapy Development for Coronavirus Infection www. Rius Medical has made it its mission to further support the cell and gene therapy industry by channelling its expertise into developing technologies that enables “scale up” manufacturing processes.

In the latest March 2020 updates to investors you will find a choice regarding a EUR 20,000 investment either as a Classical LOAN (1 year maturity, yet full repayment at the latest April 2020) with 30% interest p.a or through a Convertible Loan at a discounted rate of0,50 EUR per share that implies 2.160.000 EUR financial benefits for FIVE products, if not 420.000 EUR financial benefits for TWO products at year 2 (i.e. December 2021).

Are you against a 3 minutes Briefing over a telephone/Skype call on this investment opportunity?

Denis Demarais (BSc)
Founder, CEO and Chief Scientific Officer

Rius Medical UG (Haftungsbeschränkt)
Schulstraße 16, 72178 Waldachtal
Baden Württemberg / Germany
Tel:      +49 (0) 1577-519-8090                     Skype: djdemarais
Email: denisdemarais@riusmedical.de